Whether it’s a new product launch or an existing brand, success in OTC drugs requires a clear road map and promotion plan for how to get your product both on the shelf and off the shelf.

A new era of corporate governance has infiltrated the pharmaceutical industry within the last few years.

CADTH carried out a therapeutic review comparing the clinical effectiveness and relative cost of drugs used to treat retinal conditions.

Bill 92, An Act to extend the powers of the Régie de l’assurance maladie du Québec (RAMQ) and to amend various legislative provisions was introduced in the Quebec National Assembly in early April.

On April 13, The Quebec Health Minister Gaetan Barrette finally published in the Quebec Official Gazette the terms of the new professional allowances (PA’s).

ODB announces no new EAP approvals for Remicade.

Looking to strengthen its position in the Canadian pharmaceutical supply chain, McKesson has agreed to acquire Rexall Health from the Katz Group, a deal that’s expected to close late in 2016.

CADTH reached out in the fall asking for input into a new policy whereby confidential price submissions would no longer be accepted; all submitted prices would be made public and transparent.

In the most recent Ontario Drug Benefit Formulary Summary of Changes, Hospira’s subsequent entry biologic (SEB), INFLECTRA (infliximab) received listing for the following indications.